Download presentation
Presentation is loading. Please wait.
Published byΘυώνη Θεοτόκης Modified over 6 years ago
1
Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps Bruce K. Tan, MD, Quan-Zhen Li, PhD, Lydia Suh, BSc, Atsushi Kato, PhD, David B. Conley, MD, Rakesh K. Chandra, MD, Jinchun Zhou, PhD, James Norton, MS, Roderick Carter, MS, Monique Hinchcliff, MD, Kathleen Harris, MS, Anju Peters, MD, Leslie C. Grammer, MD, Robert C. Kern, MD, Chandra Mohan, MD, PhD, Robert P. Schleimer, PhD Journal of Allergy and Clinical Immunology Volume 128, Issue 6, Pages e1 (December 2011) DOI: /j.jaci Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions
2
Fig 1 Total and anti-dsDNA levels in nasal tissue. A, Total IgG levels. B, Total IgA levels. C and D, Anti-dsDNA levels of IgA (Fig 1, C) and IgG (Fig 1, D) subtypes. The dotted line represents the mean + 3 SDs of the levels of autoantibodies found in control nasal tissue. All analyses had a significant Kruskal-Wallis test result. ∗Significant post hoc Dunn test result. Results are normalized to total protein levels. IT, Inferior turbinate; P, nasal polyp; U, uncinate process. Journal of Allergy and Clinical Immunology , e1DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions
3
Fig 2 Correlation of anti-dsDNA antibody levels. A, Anti-dsDNA IgG level normalized to total IgG level. This analysis had a significant Kruskal-Wallis test, but results of post hoc testing were not significant. B, Anti-dsDNA IgG levels did not correlate with total IgG levels in nasal polyp tissue. C, Conversely, anti-dsDNA IgG levels correlated with total IgG levels in nasal tissue from control subjects and patients with CRSsNP. D, Anti-dsDNA IgG and IgA levels in nasal polyps are positively correlated. In 1 patient (marked by o) no detectable total IgA was measured in nasal tissue, raising the possibility of an IgA deficiency, and we excluded this sample from the analysis in Fig 2, D. Except for Fig 2, A, all results are normalized to the total protein concentration. IT, Inferior turbinate; P, nasal polyp; U, uncinate process. Journal of Allergy and Clinical Immunology , e1DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions
4
Fig 3 Correlation between anti-dsDNA levels in nasal polyps and clinical parameters. A, Anti-dsDNA IgG levels in recurrent nasal polyps were increased compared with those seen in patients undergoing initial nasal polyp surgery. B, Total immunoglobulin levels were not correlated with surgical status. C, Frequency of increased anti-dsDNA IgG levels in different subgroups. D and E, Anti-dsDNA antibodies are not differentially found in asthmatic patients (Fig 3, D) and atopic patients (Fig 3, E). F, Higher-grade polyps have higher anti-dsDNA levels. All results are normalized to total protein levels. Journal of Allergy and Clinical Immunology , e1DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions
5
Fig 4 Immunofluorescence of nasal tissue. A and B, IgG direct immunofluorescence in nasal polyp (green fluorescence; Fig 4, A) and control nasal uncinate tissue showing scattered plasma cells (red arrow; Fig 4, B). C and D, Indirect immunofluorescence of control uncinate tissue incubated with tissue extract from a control subject (Fig 4, C) and nasal polyp extract from a patient with an increased anti-dsDNA autoantibody level (Fig 4, D). Nuclei were counterstained with 4′-6-diamidino-2-phenylindole dihydrochloride (blue fluorescence), and IgG was labeled with anti-IgG (green fluorescence). Numbers in white, Normalized anti-dsDNA IgG levels found in each of the tissue extracts. E, Hep-2 assay on a nasal polyp extract from the same patient. F, Nuclear staining intensity of samples analyzed on Hep-2 assay. Journal of Allergy and Clinical Immunology , e1DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.